Targeting RAS mutants in malignancies: successes, failures, and reasons for hope.

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• RAS genes are frequently mutated oncogenes critical in cancer development.
• RAS mutations (KRAS, HRAS, NRAS) vary by tissue, posing therapeutic challenges.
• Existing RAS-targeted therapies, like KRAS^G12C inhibitors, show limited clinical efficacy for many mutants.

Purpose of the Study:

• To review novel targeted therapies for various RAS mutations.
• To elucidate mechanisms of action for emerging RAS-targeted treatments.
• To assess the efficacy of new therapeutic strategies against RAS-driven malignancies.

Main Methods:

• Literature review of preclinical and clinical studies on RAS-targeted therapies.
• Analysis of mechanisms for allele-specific inhibitors, combination therapies, immunotherapies, and metabolism-associated therapies.
• Synthesis of data on efficacy and challenges in targeting diverse RAS mutants.

Main Results:

• KRAS allele-specific inhibitors show promise but target only specific mutations.
• Combination therapies may overcome resistance and enhance efficacy.
• Immunotherapies and metabolism-associated therapies represent novel approaches for RAS-mutant cancers.

Conclusions:

• Targeting diverse RAS mutants requires a multifaceted therapeutic approach.
• Further research into RAS signaling, metabolism, and the immune microenvironment is crucial.
• Novel therapies hold potential for improving outcomes in RAS-driven cancers.